List view / Grid view
26 August 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adriana Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014...
18 August 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis...
24 July 2014 | By Biogen Idec
Biogen Idec announced that the European Commission has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a)...
16 July 2014 | By Biogen Idec
Biogen Idec announced a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis across the country...
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
30 May 2014 | By Biogen Idec
Biogen Idec received a positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency for the marketing authorisation of PLEGRIDY...
30 May 2014 | By Biogen Idec
Biogen Idec announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis therapies are being featured during two neurology conferences...
12 May 2014 | By Biogen Idec
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine...
1 May 2014 | By Biogen Idec
Biogen Idec announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis patients with confirmed improvement in walking speed...
30 April 2014 | By Biogen Idec
Additional real-world data show tolerability profile consistent with pivotal studies...
29 April 2014 | By Biogen Idec
Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY™ (peginterferon beta-1a) in people with relapsing forms of multiple sclerosis...
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
14 April 2014 | By Biogen Idec
Biogen Idec will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology Annual Meeting...
10 April 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014...
21 March 2014 | By Biogen Idec
The approval of ALPROLIX is first significant advance in hemophilia B treatment in more than 17 years ...
